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Background: Yukyung karne (YK) is a traditional Tibetan formulation used for many centuries for the treatment of
ovarian cancer. However, the pharmacological basis of its anticancer property is not well understood. In the present
study, the anticancer property of YK was investigated in cell culture.
Methods: The growth inhibitory property of YK was evaluated in SKOV6, IHH, HepG2 and HEK293 cell lines using
MTT assay. The pro-apoptotic activity of drug was analyzed by terminal deoxynuleotidyl transferase dUTP nick end
labeling (TUNEL) and DNA fragmentation assays. Confocal microscopy was used to show the release of cytochrome
c and its co-localization with mitochondria with the help of dsRed mitotracker in SKOV6 cells. The inhibition in cell
proliferation was also visualized by confocal microscopy after BrDU incorporation. The activation of tumor suppressor
p53 was evaluated by Western blotting while VEGF levels in culture supernatant were measured by a colorimetric
method.
Results: YK specifically and efficiently induced apoptotic killing of the human ovarian cancer SKOV6 cells as indicated
by increased DNA fragmentation and nick end DNA labeling. Confocal microscopy suggested inhibition of cell
proliferation and increase in cytochrome c release via perturbation in mitochondrial membrane potential (Δψm).
Further, YK up-regulated the expression of tumor suppressor p53 and key cyclin-dependent kinase inhibitor p21, and
inhibited VEGF secretion by cells. Interestingly, YK also exhibited a synergy with paclitaxel which is a well-known
anti-cancer therapeutic drug.
Conclusions: The pharmacological properties of YK to impose growth arrest and trigger pro-apoptotic death in
cells amply justify its usage in primary as well as adjunct therapy for ovarian cancer.
Keywords: Yukyung Karne, Traditional Tibetan medicine, Ovarian cancer, Apoptosis, Mitochondria membrane potentialBackground
Ovarian cancer is one of the most lethal gynecological
malignancies and a leading cause of cancer related death
in women [1]. The conventional treatment regimen for
ovarian cancer includes combination of platinum based
chemotherapy, surgery and radiation [2]. However, none
of these therapies have impacted the overall survival rate
significantly [3]. Despite several advancements made
during past few decades, there is enough scope for de-
veloping new methods and therapeutic agents for effect-
ive treatment of ovarian cancer.
Natural products are excellent sources of complex che-
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unless otherwise stated.value [4]. Dietary phytochemicals such as curcumin [5]
and Silibinin [6] have been identified as two major natural
anticancer agents. Curcumin and Silibinin have been ex-
tensively used in the traditional medical system in Asia.
Traditional Tibetan medicine (TTM) with over 2000 years
old legacy of holistic and naturopathic approach integrates
diet, behaviour, lifestyle, herbs and accessory therapies are
integrated to treat the root cause of disease [7]. The main
constituents of the Tibetan medicine are Terminalia
chebula (Aru ra), Terminalia belerica (Baru ra) and
Emblica officanalis (Kyuru ra) popularly known in Tibetan
as Aru-Baru-Kyuru in a ratio of 2:1:1 just as Triphala in
Ayurveda [8]. TTM are mostly multi-ingredient formula-
tion comprising 3 to 150 herbs and minerals to combat
multifactorial diseases like cancer [9]. Many Tibetan med-
icines are considered safe, effective, non-toxic and most ofal Ltd. This is an Open Access article distributed under the terms of the Creative
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eases [10-12]. Earlier we reported that Thapring, a TTM
used for the treatment of chronic liver diseases, can inhibit
cell proliferation and induce apoptosis in a transgenic
mouse model of hepatocellular carcinoma [13]. Since
ovarian cancer is difficult to treat and relapse rate is
quite high, many patients opt for complementary ther-
apy to ease stress, symptoms and better survival. Inter-
estingly, the therapeutic response of another TTM
formulation -Yukyung Karne (YK) [14] has shown
promising results by providing relief to the ovarian
cancer patients. In the present study, we provide evi-
dence based mechanistic insights into the anticancer
properties of YK.
Methods
Chemicals, reagents and kits
Paclitaxel was purchased from Calbiochem, Propidium iod-
ide, methanol, DMSO and 3-[4,5-dimethylthiazol-2-yl]-2,5
diphenyltetrazolium bromide (MTT) reagents were pro-
cured from Sigma Aldrich. DeadEnd Fluorometric TUNEL
system was from Promega. JC1dye-5,5′,6,′-tetrachloro-1,
1′, 3, 3′ tetraethylbenzimidazolylcarbocyanine iodide was
from Molecular Probes Inc., Eugene, USA. Enhanced
chemiluminescence (ECL) reagent and antibodies were
from Santa Cruz, USA while the VEGF quantikine ELISA
kit was from R& D system (Minneapolis, USA). Dulbecco-
modified Eagle’s medium (DMEM), fetal bovine serum
(FBS), streptomycin and penicillin were from Gibco-BRL,
USA. Lipofectamine 2000 was from Invitrogen, USA
while the BrdU labeling kit was from Roche Diagnos-
tics, Indianapolis, USA.
Plant material
Yukyung karne was purchased from the Tibetan Medical
and Astrological Institute (TMAI), Dharamshala, India.
YK was dissolved in glass-distilled water and diluted ap-
propriately for use in our experiments. No extraction
step was involved. According to Tibetan Pharmacopeia
[14], YK comprises of a mixture of root of Saussurea
lappa (C.B. Clarke) (family: Asteraceae), fruit of Emblica
Officinalis (L) (family: Euphorbiaceae), leaves of Adhatoda
vasica (NEES) (family: Acanthaceae), seeds of Elletra
cardomomum (L) (family: Zingiberaceae), fruit of Piper
longum (L) (family: Piperaceae), whole plant part of
Dracocephyllum tanguticum (Maxim) (family: Lamiaceae),
root of Zingiber officinalis (Roscoe) (family: Zingiberaceae),
seed of Coriandrum sativum (L) (family: Apiaceae), whole
plant of Meconopsis horridula (Hook) (Papaveraceae), root
of Corydalis hendersoni (Fedde) (family: Fumariaceae),
seeds of Embelia ribes (Burm. F) (Family:Myrsinaceae),
Delphinium brunonianum (Royale) (family: Ranunculaceae),
fruit of Terminalia chebula (Rety) (family: Combretaceae),
root of Acorus calamus (L) (family: Araceae), root ofAconitum ferox (Wall.ex Ser) (family: Ranunculaceae),
resin of Commiphora mukul (Hook) (family: Burseraceae)
and a mineral ingredient. All the herbs were identified by
Dr. Tsering Norbu (Menrampa) and the voucher numbers
of plant specimens are available at the herbarium depart-
ment of TMAI for reference.
Cell culture and transfection
Ovarian cancer cell line SKOV6 was a kind gift of Dr. Anil
Suri (National Institute of Immunology, New Delhi). The
human hepatoma cells Huh7 was a kind gift from Dr. A.
Siddiqui (University of Colorado, Denver). The immortal-
ized human hepatocytes (IHH) were kindly provided by
Dr. F. Danniel, Institut National de la Santé et de la
Recherche Médicale Unite 481, Universite Paris 7, Paris,
France. HepG2, HEK 293 (CRL-1573) and A549 (CCL-
185) cells were purchased from ATCC. All cultures were
grown in DMEM supplemented with 10% FBS, penicillin
100 μg/ml and streptomycin (100 μg/ml) incubated at
37°C in a humidified chamber and 5% CO2 atmos-
phere. Cells were seeded at a density of 0.6 million per
60 mm dish and transfected using Lipofectamine 2000
(Invitrogen) as per manufacturer’s protocol. For track-
ing cytochrome c localization, pEGFP-cytochrome c
(1 μg) was co-transfected with pDsRed Mitotracker (1 μg)
and analyzed by confocal microscopy (Nikon A1R) Japan.
MTT assay
Cell viability was analyzed by MTT colorimetric assay as
described by van de Loosdrecht et al. [15]. Briefly, cells
were seeded at density of 0.4 × 106 cells per 60 mm dish,
allowed to settle overnight and treated with different
concentrations of YK (1, 10, 100 μg/ml) for 24 h. Cells
were washed with DMEM without phenol red and incu-
bated with MTT reagent for 45 min at 37°C in dark.
The formazon crystals were solubilized in dimethyl sulf-
oxide and the absorbance was recorded at 560 nm. Un-
treated cells were used as control of viability (100%).
The mean absorbance values of three experiments were
expressed as percentage of viability in relative to control.
Cell proliferation assay
The BrdU incorporation assay was performed using
BrdU labelling kit (Roche Diagnostics, Indianapolis, IN,
USA) as per manufacturer’s protocol. Nuclei were stained
with DAPI (blue) while the BrdU incorporation was
detected using goat anti-mouse-conjugated to FITC
(green). The distribution of BrdU positive cells was
shown as bar diagrams.
Detection of DNA fragmentation
Cells were treated with different concentrations of YK
for 24 h. Assay was carried out as per Peng et al. [16].
Briefly cells were harvested and treated with 100 μl lysis
Table 1 Effect of YK on VEGF secretion from SKOV6 cells
Sample VEGF ± SEM (pg/ml)
Control 2.6 ± 0.057
Paclitaxel 2.10 ± 0.01*
Paclitaxel + YK 1.84 ± 0.02*
YK 1.53 ± 0.05*
*, Level of significance p Value <0.001.
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RNase A at 56°C and followed by Proteinase K digestion
at 37°C for 2 h. DNA was precipitated with 2.5 volume
of cold absolute ethanol. The DNA pellet was dissolved
in TE buffer and resolved by electrophoresis in a 2%
agarose gel.
Cell cycle analysis by FACS
Equal number of cells (0.6-0.8 × 106) were seeded in
each 60 mm dish and after 24 h were treated with YK
(100 μg/ml). Cell cycle analysis was performed as men-
tioned by Mukherji et al. [17]. Briefly cells were fixed
and stained with propidium iodide solution (50 μg/ml
PI, 10 μg/ml RNase) and the data was acquired using a
FACScan flow cytometer equipped with CellQuest soft-
ware (Becton Dickinson, San Jose, CA, USA).
TUNEL assay
SKOV6 cells were treated with YK and the level of apop-
tosis was detected by TUNEL assay using DeadEndTM
Flourometric TUNEL kit (Promega). The assay was done
as per manufacturer’s protocol. Cells were mounted
using Antifade with DAPI and detected localized green
fluorescence of apoptotic cells by confocal microscopy
(Nikon A1R) Japan.
Determination of mitochondrial membrane potential
(ΔΨm)
For analysis of mitochondrial membrane potential, cells
were seeded in 12 well plate overnight followed by treat-
ment with YK for another 24 h and then stained with
JC1 dye for 15 min at 37°C in 5% CO2 incubator. Cells
were mounted with antifade mounting medium (Invitro-
gen, USA) and visualized at 488 nm and 590 nm using
confocal microscopy (Nikon A1R) Japan.
Estimation of vascular endothelial growth factor (VEGF)
The VEGF levels were measured as per manufacturer’s
protocol (R&D system, Minneapolis). Briefly, supernatant
of the experimental set of cultured cells were collected for
VEGF assay. Each well was washed with wash buffer and
100 μl of the VEGF conjugate was added to each well.
After repeated washing step, 100 μl of substrate solution
was added to each well followed by addition of 100 μl of
stop solution and mixed it gently. The OD was measured
at 450 nm.
High performance liquid chromatography (HPLC)
The fingerprints of YK samples were monitored on a
Shimadzu reverse-phase HPLC system (C18 column -
250 mm, 4.6 mm) with SCl-10AVp system controller
and SPD-10AVvp UV–vis detector. The mobile phase
(acetonitrile and water) was degassed and filtered through
0.2 μm membrane filter before pumping into the HPLCsystem. A linear gradient of acetonitrile from 5% to 95%
over 55 min at a flow rate of 1 ml/min was maintained
and the samples were monitored at 220 and 280 nm using
Photo Diode Array (PDA) detector. The YK samples
(20 μg in 200 μl of glass distilled water) were used for
injection.
Western blotting
Cell lysates were prepared in cell lysis buffer. (Promega,
USA) Protein concentration was determined by Bradford
method. Samples with equal amounts of protein were
prepared in 2x sample loading buffer (100 mM Tris–HCl
pH6.8, 200 mM dithiothreitol, 4% SDS, 0.2% bromophenol
blue and 20% glycerol) and resolved on 10-15% SDS-
PAGE. The protein bands were visualized using the
Enhanced chemiluminescent reagent (Santa Cruz, USA)
according to supplier’s protocol and the image captured
by Fluorchem M (Protein Simple, USA).
Statistical analysis
Statistical significance of results in Tables 1 and 2
were calculated by Duncan’s test using SPSS software
(Version 17). All other data were analyzed by Student’s
t test. p value <0.05 was considered as significant.
Results
Induction of apoptosis in ovarian cancer cells
An important challenge faced in chemotherapy is the ad-
verse effect of drugs on the normal healthy cells. Most
of the anticancer treatment regimen affects both cancer-
ous as well as healthy cells. In order to establish the spe-
cificity of YK for ovarian cancer, we examined its effect
on various cell lines by MTTassay. As shown in Figure 1A,
we observed a selective induction of cell death by YK in
ovarian and cervical cancer cell lines (SKOV6 and HeLa
cells respectively). Interestingly YK did not induce apop-
tosis in IHH cells indicative of its specificity to target can-
cerous cells. Since YK exhibited a dramatic cytotoxic
effect on SKOV6 cell line, it was selected for further stud-
ies. Paclitaxel a commonly used anticancer drug was used
as a reference drug. As shown in Figure 1B, cells treated
with paclitaxel (10 nM) showed a significant increase in
cell death (p <0.005). Further MTT assay showed that
treatment of YK in combination with paclitaxel aug-
mented the apoptotic response induced by paclitaxel alone
Table 2 Effect of anticancer drugs on cell cycle
progression of SKOV6 cells
Sample G1 S G2
Control 59.63 ± 2.0 17.58 ± 2.8 17.83 ± 1.09
Paclitaxel 35.0 ± 9.07* 16.65 ± 2.34 19.93 ± 3.3
Paclitaxel + YK 38.6 ± 6.38* 17.0 ± 1.5 18.18 ± 3.8
YK 73.4 ± 1.5 15.46 ± 3.09 14.18 ± 0.64
*, Level of significance: p Value < 0.004 v. control.
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acteristic feature of apoptosis, we performed DNA frag-
mentation assay on the YK treated SKOV6 cells. As a
noticeable fragmentation of DNA was seen at 100 μg/ml
of YK (Figure 2A), all subsequent experiments were car-
ried out at this concentration. We also performed TUNEL
assay to confirm the observation on YK induced apoptosis
of SKOV6 cells. As shown in Figure 2B, a significant num-
ber of TUNEL positive cells were detected in the YK
treated cells (p <0.001) whereas no TUNEL positive cells
were observed in untreated control SKOV6 cells. These
data confirmed the apoptotic action of YK on ovarian can-
cer cell line.Induction of tumor suppressors and cell cycle regulators
Given the key role of p53 as tumor suppressor protein
in cancer prevention [18], we also studied the ability of
YK to enhance p53 expression in the treated cells. Pacli-
taxel, a well-known therapeutic anticancer drug, was in-
cluded as positive control as well as to evaluate its
synergy with YK. We observed a marked increase in the
cellular p53 levels after YK treatment (Figure 2C). How-
ever, the level of Mdm2 was down-regulated leading to



















Figure 1 Growth inhibitory effect of YK on different cell lines. A. HEK2
different doses of YK (1, 10, 100 μg/ml) and analyzed for cell viability by MT
and the cell viability was measured as above. Results are represented as m
p <0.005.regulation of pTEN, a potent tumor suppressor and p21,
a potent inhibitor of cell proliferation and replication
(Figure 2C). These results were further complemented
by decrease in proliferation marker PCNA and cell cycle
regulator cyclin B suggesting reduced proliferation of
SKOV6 cells upon YK treatment (Figure 2C). Thus, p53
the most appealing target for mechanism-driven antican-
cer drug discovery, also appeared to play an important
role in YK induced killing of cancer cell. Further, restor-
ation of p53 functions in cancer cells by YK treatment
could be an important strategy to combat cancer.Role of mitochondria-dependent intrinsic pathway in
apoptosis
Since, mitochondria plays a key role in energy metabol-
ism, and proving to be the novel target in killing cancer-
ous cells [19], we sought to determine the effect of YK
on mitochondrial function with the help of cationic JC1
dye. Exposure of cells to YK led to the disappearance of
red fluorescence and increase in the green fluorescence
in most cells combined with a significant reduction
(p <0.001) in mitochondrial membrane potential. (Figure 3A)
Further, YK along with Paclitaxel perturbed mitochondrial
membrane potential to a significant level (p <0.05) as com-
pared to only paclitaxel treatment (Figure 3B).
Since release of cytochrome c from depolarized mito-
chondria and binding to Apaf1 are crucial steps in the
formation of apoptosome, next we monitored the release
of GFP-tagged cytochrome c from YK treated SKOV6
cells by confocal microscopy. Interestingly a significant
increase was observed in cytochrome c released from
dsRed Mitotracker-tagged mitochondria as indicated by
a significant decrease (p <0.001) in co-localization of cyto-
























93T, A549, HepG2, Hela, IHH and SKOV6 cells were treated with
T assay. B. SKOV6 cells was treated with YK and/ or paclitaxel (10 nM)
ean of three independent experiments ± S.E.M. Level of significance; *,
µg
µg
Figure 2 Induction of apoptosis by YK in SKOV6 ovarian cells. A, Cells were treated with indicated doses of YK and/or paclitaxel [Lanes: 1-Control,
2-Paclitaxel 10nM, 3-Pac + YK (10nM+ 100 μg/ml), 4–7 YK (1, 10, 100, and 200 μg/ml respectively) and 8-50 bp ladder] for 24 h. Genomic DNA was isolated
and resolved by agarose gel electrophoresis. B, Cells were treated with different doses of YK (1, 10, 100 μg/ml) was visualized by TUNEL assay. The
TUNEL positive cells (stained by FITC) were counted from random fields and are presented in the graph. Nuclei were visualized by DAPI
staining (blue). Results are represented as mean of three independent experiments ± SD. Level of significance; *, p <0.001. C, Induction of
cell cycle regulators. SKOV6 cells were treated for 24 h with YK (100 μg/ml), Paclitaxel (Pac) (10 μM) or both and the expression of p21, p53,
Mdm2, cyclin B1, and PCNA was verified by western blot. GAPDH was used as internal control.
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mitochondria-dependent intrinsic apoptotic pathway is
involved in YK-induced cell death.
Anti angiogenic effect of YK
Sustained angiogenesis is another hallmark of cancer.
Neo-angiogenesis is essential for supplying nutrients to
the fast growing cancerous cells. Therefore starving the
cancer cells is one of the most promising approach to
fight cancer [20]. Of various growth factors that regulate
angiogenesis, VEGF is believed to be the most important
factor. To explore if YK could block angiogenesis, we
used ELISA to measure the levels of VEGF secreted by
the YK treated cells. Duncan analysis of these results
(Table 1) revealed that all the four groups were signifi-
cantly different from each other and that the VEGF levels
in treated groups were lower than control (p <0.05).
Another most prominent change seen in cancer is the
deregulation of cell cycle [21]. Anticancer agents on the
other hand, may exert their effect by halting the cell
cycle progression [22]. Therefore, next we studied the
cell cycle distribution of SKOV6 cells treated with YK by
FACS. Duncan test revealed that two groups of significant
difference exist. The paclitaxel- and paclitaxel + YK-treatedgroups are not different from each other but are different
from control- and YK-treated groups in the cells of G1
phase (p <0.05). Further, the control and YK groups are
not different from each other. No significant difference was
observed in four groups of cells of S and G2 phases.
Since, YK could abrogate cell cycle progression we also
checked cell proliferation status using BrdU incorpor-
ation. YK treatment led to a significant reduction in the
number of the BrdU positive cells. Further combined
treatment with YK and paclitaxel showed the maximum
reduction in proliferating cells. (Figure 4B) Together,
these observations suggested that YK can inhibit prolif-
eration by inducing cell cycle arrest at G1 phase and
thus could be useful as an effective anticancer agent.
Discussion
Despite significant advances made in the area of cancer
chemotherapy, chemo resistance continues to be a major
problem associated with the outcome of treatment [23].
Further, efficient targeting of cancer cells still remains a
major challenge for the scientists. Therapies which are
capable of inducing selective apoptosis in cancer cells
are gaining attention as new potential alternative. The
conventional treatment for ovarian cancer includes the




































































Figure 3 Alterations in mitochondrial functions following YK treatment of SKOV6 cells. A, Confocal images of JC1 stained cells treated with
YK for 24 h. The green fluorescence shows depolarized mitochondria (monomer), whereas red fluorescence shows hyperpolarized (aggregates)
mitochondria. B, Cells treated with YK for 24 h showing the release of cytochrome c from mitochondria during apoptosis. Cells were co-transfected
with cytochrome c-GFP fusion construct and dsRed mitotracker and visualized by confocal microscopy. Green represents cytochrome c, red mitochondria
and orange indicates co-localization of cytochrome c and mitochondria. Results in both panels are represented as mean of three independent
experiments ± SD Level of significance; *, p <0.05; **, p <0.001.
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postoperative chemotherapy for advanced cancer pa-
tients [24], but the adverse effects are often inevitable. In
this report, we provide a scientific basis for the clinical
outcome of YK, a TTM that has been used in regular
clinical practice for targeted therapy of ovarian cancer.
Besides we studied the complementary action of YK with
a well-known anticancer drug paclitaxel. We found that
YK can induce cytotoxicity specifically in cancer cells
and spared immortalized cell lines such as IHH. The
YK- treated cells exhibited typical characteristic of apop-
tosis such as DNA fragmentation and apoptotic cell
death as evident from the MTT and TUNEL assays
(Figures 1 and 2).
Given the central role of mitochondria in initiating the
apoptotic process by releasing cytochrome c, we studied the
effect of YK on mitochondria and asked if the YK-inducedapoptosis was mitochondria dependent. We observed that
YK perturbed the mitochondrial membrane potential which
triggered the release of cytochrome c which in turn acti-
vated the apoptotic machinery [25].
One of the key mechanisms of action of anticancer
drug on cell is to halt cell cycle progression [26]. We
also investigated the effect of YK on cell cycle progres-
sion in cancer cells by FACS analysis. Interestingly, we
found that treatment with YK led to the arrest of SKOV
6 cells in G1 phase suggesting its growth inhibitory
property (Figure 4A). This was further supported by the
down regulation of cyclin B in the YK- treated cells
which otherwise allows the cell cycle progression to S
phase. Nevertheless, these results did not rule out the
possibility of activation of some crucial cell cycle check-
point inhibitors in the treated cells in order to prevent
their proliferation. In this context it was interesting to


























Figure 4 Inhibition of cell proliferation in the presence of YK. SKOV 6 cells were treated with paclitaxel (10nM) and/or YK 100 μg/ml for 24 h
and analyzed by confocal microscopy for BrdU incorporation for DNA synthesis. Results are represented as mean of three independent
experiments ± SD. Level of significance; *, p <0.02, **, p <0.002.
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cells which may be responsible for their G1 arrest as also
supported by the down regulation of PCNA (prolifera-
tion marker) in these cells [27]. The most important ob-
servation made in the present study was the ability of
YK to synergize with the action of paclitaxel - a widely
used anticancer drug. Since most anticancer therapies
act by induction of apoptosis which often lead to resist-
ance, the combinatorial treatment could be advanta-
geous as a potent strategy to bypass resistance [28]. The
synergy between YK and paclitaxel was seen at all levels
including the inhibition of cell cycle progression and
even activation of p53 (Figure 2C). Angiogenesis is a key
requirement for tumorigenesis and blocking the process
appears to be an effective strategy to combat cancer
[29]. Many tumors show increased expression of VEGF
compared to normal tissues [30]. Therefore, therapies
directed against VEGF or its receptors hold great prom-
ise in cancer treatment. Incidentally, YK treatment also
led to a reduction in VEGF secretion by cancer cells in-
dicating the anti-proliferative signaling by YK (Table 1).
Since the analytical profiling of YK reproducibly showed
the presence of some specific components in this formu-
lation (Additional file 1: Figure S1), it will be desirable to
study each molecular component of this formulation to
understand the pharmacological principles of YK.
Conclusions
YK is an ovarian cancer-specific and effective traditional
Tibetan formulation bearing the following anticancer
properties: (i) imposes G1 arrest of cells by activating
p53, (ii) induces cytochrome c release from mito-
chondria, and (iii) inhibits angiogenesis. Further, YK
could be of immense pharmacological significance asit complements the action of known anticancer drugs
like paclitaxel which may allow improving the efficacy
and potency of conventional drugs and reduce side ef-
fects. Thus, YK appears to be a strong candidate as
novel therapeutic for the ovarian cancer patients.
Additional file
Additional file 1: Figure S1. Analytical profile of Yukyung Karne (YK). YK
sample (300 mg in water) was analyzed by reverse phase-HPLC (Shimadzu)
on a C18 column using 2% acetonitrile gradient from 5% to 95% over a 55
minute run (flow rate of 1.0ml/min). Sample detection was done at 220 and
280nm under ambient temperature conditions.
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